Title
Category
Credits
Event date
Cost
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Join Drs. Neal Shore, Gautam Jayram, and Nurse Tanya O’Neal as they discuss clinical considerations for managing immune-related adverse events that may occur at any time during therapy and, as of yet, there is no reliable means to predict who will develop them. If irAEs do develop, it is essential to arrive at an early diagnosis and use aggressive systemic corticosteroids when necessary to prevent life-threatening consequences.
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
As the treatment paradigm for bladder cancer continuously evolves, all members of the oncology healthcare team must be equipped to evolve with it to ensure optimal patient care. With this evolution comes many questions for the bladder cancer treatment team. Join Drs. Neal Shore, Arjun Balar, Lidia Lopez, and Nurse Joanie Pfahl as they examine the new paradigm of bladder treatment using ICIs, and discuss the important role of each person on the treatment team.
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Immunotherapies are revolutionizing many cancer treatment regimens and show promise in locally advanced or metastatic bladder cancer. Immune checkpoint inhibitors are attempting to fill an unmet need in relapsed disease and biomarkers may assist in identifying patients most likely to respond. Though trial data are still evolving, mounting evidence suggests a role for immunotherapy earlier in the disease spectrum, as front-line therapy for cisplatin-ineligible patients, and in combinatorial regimens in late-stage disease. Join Drs.
  • Oncology
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
It is estimated that there are >81,000 new cases of metastatic urothelial bladder cancer (mUBC) in the U.S each year, resulting in more than 17,000 bladder cancer specific deaths. For more than three decades, systemic platinum-based chemotherapy has been the standard first-line treatment for patients with inoperable or advanced metastatic bladder cancer.